Which advantages over its rivals hold up, and why are they hard to copy?
Scope Fluidics' differentiating bet is density: its UNI FAST Pro GN panel assesses many antibiotics and many drug-bug combinations in a single run capped at six hours, covering 34 antibiotics across 54 antibiotic-bacterium combinations, including the ESBL resistance mechanism, and combining a broad antibiotic range with quantitative and qualitative susceptibility assessment.
The Management Board expects that certifying the GN panel first will widen the range of BACTEROMIC panels on sale sooner.
2Risk Factors
Which risks could break the thesis, and what would warn of them?
Both the payout trigger and the schedule rest on PARP's approval, so the project has a single point of exposure: the PLN 14.4 million flows in installments only while Hybolic satisfies the objectives of its PARP agreement, and Hybolic will seek PARP approval for a revised project schedule almost 15 months after the funding application was filed.
The total project cost that the funding application reports is PLN 24.1 million.
3Product Overview
What does the product do for its buyer, and how is it delivered?
Bacteromic's entry into these European markets hands exclusivity and local registration to its partner under a two-year exclusive framework distribution agreement signed with the Austrian firm Biomedica Medizinprodukte GmbH.
Biomedica distributes medical devices and in vitro diagnostics, life science products as well as clinical IT solutions, and has been active nearly 50 years in the market.
Scope Fluidics
Scope Fluidics is a biotechnology company developing microfluidic projects for medical diagnostics and healthcare.